On the stock market since 2021, it operates in the world of health and science. It has 461 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 56% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 40% a year on average.
Sales run at $134.5M a year. A small number, but proof the product has real buyers.
There is $228.1M in the vault; even if every debt were paid off, $217.1M would remain.
A loss of $38.9M against $134.5M in annual sales. And on top of that, sales fell from the year before.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 27/100. For a turnaround signal, the stock first needs to close the gap with the market.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 39/100.
On our five-subject report card, RXST sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RXST is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.